Richard Gregory
Directeur/Membre du Conseil chez CANBRIDGE PHARMACEUTICALS INC.
Postes actifs de Richard Gregory
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 21/04/2020 | - |
| Independent Dir/Board Member | 21/04/2020 | - |
Historique de carrière de Richard Gregory
Anciens postes connus de Richard Gregory
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 18/10/2016 | 27/04/2023 |
| Independent Dir/Board Member | 18/10/2016 | 27/04/2023 | |
| IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 05/01/2015 | 30/08/2019 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2003 | 01/01/2014 |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Directeur/Membre du Conseil | 28/04/2020 | - |
| Directeur Technique/Scientifique/R&D | 28/04/2020 | - | |
| Q32 BIO INC. | Directeur/Membre du Conseil | 01/01/2015 | - |
| Independent Dir/Board Member | 01/01/2015 | - |
Formation de Richard Gregory
| University of Massachusetts | Doctorate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
| Canada | 2 |
| Chine | 2 |
Opérationnelle
| Director/Board Member | 4 |
| Chief Tech/Sci/R&D Officer | 3 |
| Independent Dir/Board Member | 3 |
Sectorielle
| Health Technology | 7 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
- Bourse
- Insiders
- Richard Gregory
- Expérience
